Neelufar Mozaffarian - 29 May 2025 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Director
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
29 May 2025
Net transactions value
$0
Form type
4
Filing time
30 May 2025, 16:09:22 UTC
Previous filing
31 Jul 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mozaffarian Neelufar Director C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO /s/ Cindy Tahl, as Attorney-in-Fact 30 May 2025 0002031203

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Award $0 +55,000 $0.000000 55,000 29 May 2025 Common Stock 55,000 $1.32 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.
F2 The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Remarks:

Exhibit 24 - Power of Attorney